Rinvoq vs. Eticovo

• Are Rinvoq and Eticovo the Same Thing?
• What Are Possible Side Effects of Rinvoq?
• What Are Possible Side Effects of Eticovo?
• What Is Rinvoq?
• What Is Eticovo?
• What Drugs Interact with Rinvoq?
• What Drugs Interact with Eticovo?
• How Should Rinvoq Be Taken?
• How Should Eticovo Be Taken?

Rinvoq (upadacitinib) and Eticovo (etanercept-ykro) are used to treat rheumatoid arthritis.

Eticovo is also used to treat polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older.

Eticovo is biosimilar to Enbrel (etanercept).

Rinvoq and Eticovo belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor and Eticovo a tumor necrosis factor (TNF) blocker.

Side effects of Rinvoq and Eticovo that are similar include infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza) and fever.

Side effects of Rinvoq that are different from Eticovo include nausea and cough.

Side effects of Eticovo that are different from Rinvoq include injection site reactions, diarrhea, rash, itching, and hives.

Both Rinvoq and Eticovo may interact with live vaccines.

Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).

Eticovo may also interact with anakinra, abatacept, and cyclophosphamide, and sulfasalazine.

Common side effects of Rinvoq include:

• upper respiratory tract infections,
• nausea,
• cough, and
• fever

Side effects of Eticovo nclude<:/p>

• infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza),
• injection site reactions,
• diarrhea,
• rash,
• itching,
• fever, and
• hives

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older. Eticovo is biosimilar to Enbrel (etanercept).

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

Eticovo may interact with "live vaccines," anakinra, abatacept, and cyclophosphamide, and sulfasalazine. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Eticovo; it is unknown how it would affect a fetus. Eticovo passes into breast milk in low levels. Consult your doctor before breastfeeding.

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

The dose of Eticovo to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Eticovo to treat ankylosing spondylitis is 50 mg once weekly. The dose of Eticovo to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Eticovo to treat pediatric plaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.